✦ LIBER ✦

Conservative treatment for patients over 80 years with acute myelogenous leukemia

✍ Scribed by Roberto Latagliata; Giuliana Alimena; Ida Carmosino; Massimo Breccia; Paola Anticoli Borza; Velia Bongarzoni; Carolina Copia; Antonio Spadea; Beatrice Pinazzi; Natalia Frattarelli; Felicetto Ferrara; Maria Concetta Petti; Franco Mandelli

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 47 KB
Volume: 71
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.10235

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of acute myelogenous leukemia

Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: A southwest oncology group study

✍ Dr. Carolyn L. Bigelow; Kenneth Kopecky; Joe C. Files; David Head; David A. Lips 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB 👁 2 views

Thiotepa for the treatment of thrombocyt

Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia

✍ Edgardo J. Rodriguez-Monge; Jorge E. Cortes; Susan O'Brien; Moshe Talpaz; Hagop 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

## Background: Patients with chronic myelogenous leukemia (cml) occasionally experience persistent thrombocythemia despite having adequate white blood cell (wbc) counts. trimethylenethiophosphoramide (thiotepa) is an alkylating agent that significantly inhibits platelet production. ## Methods: Th

Possible association between Budd-Chiari

Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia

✍ Mevlüt Kurt; Ali Shorbagi; Kadri Altundag; Tamer Elkiran; Ibrahim Güllü; Emin Ka 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Abstract Gemtuzumab ozogamicin (GO; CMA‐676; Mylotarg™) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno‐occlusive disease has been reported to develop as a late complication

A pilot study of interleukin-2 for adult

A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission

✍ Jorge E. Cortes; Hagop M. Kantarjian; Susan O'Brien; Francis Giles; Michael J. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## BACKGROUND. Interleukin-2 (IL-2) has immunomodulatory effects, including stimulating the activity of cytotoxic T cells and natural killer cells, and inducing the generation of lymphokine-activated killer cells. The authors investigated whether IL-2 may improve the duration of complete remission

Acute nonlymphocytic leukemia 5 years af

Acute nonlymphocytic leukemia 5 years after treatment with cisplatin, vinblastine, and bleomycin for disseminated testicular cancer

✍ Gustaaf W. Van Imhoff; Dirk T. H. Sleijfer; Martijn H. Breuning; Georges J. P. A 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 397 KB 👁 2 views

The authors thank Mrs. J. van Dalen and Miss M. Aikema for excellent technical assistance.

Treatment of patients with recurrent and

Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine : A pharmacologically based regimen

✍ David W. Sternberg; William Aird; Donna Neuberg; Lynn Thompson; Kimberly MacNeil 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 2 views

## BACKGROUND. Although chemotherapy can achieve a high rate of disease remission induction in patients with newly diagnosed acute myelogenous leukemia (AML), patients with recurrent or refractory AML generally have a poorer rate of response. This study assessed the utility of mitoxantrone and inte